Clin2
NCT06685289Possibly a fitRecruiting

Donafenib and capecitabine after surgery for biliary cancer with high risk of return

Biliary Malignant Tumors

Treatments studied

Part of Cancer, Digestive system clinical trials.

This trial tests whether taking donafenib and capecitabine pills after surgery can help prevent biliary cancer from coming back in people who have a high risk of recurrence. It is for patients whose cancer was completely removed but had certain features that make recurrence more likely.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
70 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • Age between 18 and 75
  • Surgery to remove the cancer was completely successful (called R0 resection)
  • The cancer had at least one high-risk feature, like being larger or spreading to lymph nodes or blood vessels
  • No prior chemotherapy, radiation, targeted therapy, or immunotherapy before this trial
  • Must be able to take care of yourself (ECOG score of 0 or 1)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06607276Recruiting· Phase 2
Adjuvant adebrelimab and capecitabine for high-risk bile duct cancer

This trial is for people with bile duct cancer who have had surgery to remove all visible cancer but are at high risk of it coming back. It tests whether adding two medications — adebrelimab (an immunotherapy) and capecitabine (a chemotherapy pill) — after surgery can help prevent the cancer from returning.

Nanjing, Jiangsu
NCT06208462Recruiting· Phase 2
Combination therapy before surgery for high-risk bile duct cancer

This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.

Nanjing, Jiangsu
NCT06581315Recruiting
Donafenib after surgery for high-risk liver cancer

This trial tests a drug called Donafenib (a targeted therapy) taken after surgery to see if it can prevent liver cancer from coming back in people at high risk of recurrence.

Guangzhou, Guangdong
NCT07745296Not yet recruiting· Phase 3
Precision medicine after surgery for bile duct cancer

This trial tests whether matching targeted therapy to the genetic changes in your cancer can lower the chance of it coming back after surgery. You would first have your tumor tested for specific alterations, and if one is found, you may receive a drug that targets it.

NCT07790445Not yet recruiting· Phase 4
Adjuvant chemotherapy for bile duct cancer after surgery

This study tests whether giving chemotherapy directly into the liver (HAIC) plus an oral chemo pill (capecitabine) after surgery helps prevent bile duct cancer from coming back, compared to just the pill. It's for people who recently had their cancer completely removed.

Zhengzhou, Henan
NCT06699459Not yet recruiting· Phase 2
Comparing two chemotherapies for bile duct cancer that returns after surgery

This trial compares two types of chemotherapy for people whose bile duct cancer has come back after surgery. It tests if a combination of irinotecan liposomes, 5-FU, and leucovorin works better than the standard pill capecitabine.

Fuzhou, Fujian

Hear when a new Biliary Malignant Tumors trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.